Basilea Pharmaceutica (OTCMKTS:BPMUF) Reaches New 52-Week High – Time to Buy?
by Kim Johansen · The Markets DailyBasilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) shares reached a new 52-week high during trading on Monday . The company traded as high as $72.14 and last traded at $72.14, with a volume of 20 shares traded. The stock had previously closed at $59.29.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised Basilea Pharmaceutica to a “hold” rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold”.
Get Our Latest Stock Report on BPMUF
Basilea Pharmaceutica Trading Up 14.1%
The company has a fifty day simple moving average of $61.18 and a 200-day simple moving average of $63.76. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.32 and a quick ratio of 5.67.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.